Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Helio S Sader

Showing results (401-410 of 420) with videos related to

Pageof 42
Sort By:
Antimicrobial Agents and Chemotherapy|May 11, 2016
In Vitro Activity of Lefamulin Tested against Streptococcus pneumoniae with Defined Serotypes, Including Multidrug-Resistant Isolates Causing Lower Respiratory Tract Infections in the United StatesRodrigo E Mendes, David J Farrell, Robert K Flamm, et al.
Journal of Clinical Microbiology|April 19, 2013
Evaluation of vancomycin susceptibility testing for methicillin-resistant Staphylococcus aureus: comparison of Etest and three automated testing methodsMichael J Rybak, Celine Vidaillac, Helio S Sader, et al.
Journal of Clinical Microbiology|March 23, 2018
Assessment of 30/20-Microgram Disk Content versus MIC Results for Ceftazidime-Avibactam Tested against Enterobacteriaceae and Pseudomonas aeruginosaHelio S Sader, Paul R Rhomberg, Michael D Huband, et al.
The Journal of Antimicrobial Chemotherapy|March 9, 2012
Characterization of methicillin-resistant Staphylococcus aureus displaying increased MICs of ceftarolineRodrigo E Mendes, Athanassios Tsakris, Helio S Sader, et al.
Antimicrobial Agents and Chemotherapy|April 24, 2019
The Microbiology of Bloodstream Infection: 20-Year Trends from the SENTRY Antimicrobial Surveillance ProgramDaniel J Diekema, Po-Ren Hsueh, Rodrigo E Mendes, et al.
Journal of Clinical Microbiology|July 18, 2008
Characterization of vancomycin-heteroresistant Staphylococcus aureus from the metropolitan area of Detroit, Michigan, over a 22-year period (1986 to 2007)Michael J Rybak, Steve N Leonard, Kerri L Rossi, et al.
Antimicrobial Agents and Chemotherapy|March 24, 2010
Activity of ceftaroline against recent emerging serotypes of Streptococcus pneumoniae in the United StatesMichael R Jacobs, Caryn E Good, Anne R Windau, et al.
International Journal of Infectious Diseases : IJID : Official Publication of the International Society for Infectious Diseases|October 1, 2021
Ceftolozane-tazobactam activity against clinical isolates of Pseudomonas aeruginosa from ICU patients with pneumonia: United States, 2015-2018Michael A Pfaller, Dee Shortridge, Kelly A Harris, et al.
Diagnostic Microbiology and Infectious Disease|February 28, 2019
Ceftobiprole activity when tested against contemporary bacteria causing bloodstream infections in the United States (2016-2017)Michael A Pfaller, Robert K Flamm, Leonard R Duncan, et al.
Antimicrobial Agents and Chemotherapy|October 31, 2018
Ceftobiprole Activity against Gram-Positive and -Negative Pathogens Collected from the United States in 2006 and 2016Michael A Pfaller, Robert K Flamm, Rodrigo E Mendes, et al.
Pageof 42

Showing results (401-410 of 420) with videos related to

Sort By:
Pageof 42
Antimicrobial Agents and Chemotherapy|May 11, 2016
In Vitro Activity of Lefamulin Tested against Streptococcus pneumoniae with Defined Serotypes, Including Multidrug-Resistant Isolates Causing Lower Respiratory Tract Infections in the United StatesRodrigo E Mendes, David J Farrell, Robert K Flamm, et al.
Journal of Clinical Microbiology|April 19, 2013
Evaluation of vancomycin susceptibility testing for methicillin-resistant Staphylococcus aureus: comparison of Etest and three automated testing methodsMichael J Rybak, Celine Vidaillac, Helio S Sader, et al.
Journal of Clinical Microbiology|March 23, 2018
Assessment of 30/20-Microgram Disk Content versus MIC Results for Ceftazidime-Avibactam Tested against Enterobacteriaceae and Pseudomonas aeruginosaHelio S Sader, Paul R Rhomberg, Michael D Huband, et al.
The Journal of Antimicrobial Chemotherapy|March 9, 2012
Characterization of methicillin-resistant Staphylococcus aureus displaying increased MICs of ceftarolineRodrigo E Mendes, Athanassios Tsakris, Helio S Sader, et al.
Antimicrobial Agents and Chemotherapy|April 24, 2019
The Microbiology of Bloodstream Infection: 20-Year Trends from the SENTRY Antimicrobial Surveillance ProgramDaniel J Diekema, Po-Ren Hsueh, Rodrigo E Mendes, et al.
Journal of Clinical Microbiology|July 18, 2008
Characterization of vancomycin-heteroresistant Staphylococcus aureus from the metropolitan area of Detroit, Michigan, over a 22-year period (1986 to 2007)Michael J Rybak, Steve N Leonard, Kerri L Rossi, et al.
Antimicrobial Agents and Chemotherapy|March 24, 2010
Activity of ceftaroline against recent emerging serotypes of Streptococcus pneumoniae in the United StatesMichael R Jacobs, Caryn E Good, Anne R Windau, et al.
International Journal of Infectious Diseases : IJID : Official Publication of the International Society for Infectious Diseases|October 1, 2021
Ceftolozane-tazobactam activity against clinical isolates of Pseudomonas aeruginosa from ICU patients with pneumonia: United States, 2015-2018Michael A Pfaller, Dee Shortridge, Kelly A Harris, et al.
Diagnostic Microbiology and Infectious Disease|February 28, 2019
Ceftobiprole activity when tested against contemporary bacteria causing bloodstream infections in the United States (2016-2017)Michael A Pfaller, Robert K Flamm, Leonard R Duncan, et al.
Antimicrobial Agents and Chemotherapy|October 31, 2018
Ceftobiprole Activity against Gram-Positive and -Negative Pathogens Collected from the United States in 2006 and 2016Michael A Pfaller, Robert K Flamm, Rodrigo E Mendes, et al.
Pageof 42